Intellia Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Debanjana Chatterjee from JonesTrading maintained a Buy rating on the stock and has a $25.00 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Debanjana Chatterjee has given his Buy rating due to a combination of factors influencing Intellia Therapeutics’ potential growth. One of the primary reasons is the anticipated resumption of the MAGNITUDE trials, which were previously on hold due to safety concerns. The analyst’s confidence is bolstered by feedback from key opinion leaders suggesting that the trials could proceed with improved safety measures.
Additionally, upcoming data releases present opportunities for positive market reactions. The longer-term data from the Ph1/2 HAE and Ph1 ATTR-CM trials are expected to provide insights into the efficacy and safety of Intellia’s treatments. If these updates show favorable results, particularly in patient outcomes and disease stabilization, they could significantly enhance investor sentiment and drive the stock’s value upward.
According to TipRanks, Chatterjee is a 5-star analyst with an average return of 36.6% and a 70.45% success rate. Chatterjee covers the Healthcare sector, focusing on stocks such as Intellia Therapeutics, Opus Genetics, and Theravance Biopharma.
In another report released on October 30, H.C. Wainwright also maintained a Buy rating on the stock with a $18.00 price target.